Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 173,755	$ 121,627	$ 55,913
General and administrative	34,375	26,212	19,638
Total operating expenses	208,130	147,839	75,551
Loss from operations	(208,130)	(147,839)	(75,551)
Other income:
Interest income	13,077	3,989	467
Other income, net	943	2,249	2,468
Change in fair value of CVR liability	1,700	1,360	343
Total other income, net	15,720	7,598	3,278
Net loss	$ (192,410)	$ (140,241)	$ (72,273)
Net loss per share attributable to common stockholders, basic	$ (2.42)	$ (2.39)	$ (1.87)
Net loss per share attributable to common stockholders, diluted	$ (2.42)	$ (2.39)	$ (1.87)
Weighted average common shares outstanding, basic	79,657,942	58,739,713	38,730,813
Weighted average common shares outstanding, diluted	79,657,942	58,739,713	38,730,813
Comprehensive loss:
Net loss	$ (192,410)	$ (140,241)	$ (72,273)
Other comprehensive loss
Net unrealized gains (losses) on marketable securities	350	(104)	0
Total other comprehensive loss	350	(104)	0
Comprehensive loss	$ (192,060)	$ (140,345)	$ (72,273)